文献速递造血干细胞移植与细胞治疗白血病

ATG对基于TBI的清髓性预处理allo-HCT结局的影响

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
PubMed 文献 · Blood Adv · 2019-01-01

该回顾性研究分析了724例接受基于全身照射(TBI)清髓性预处理后首次异基因造血干细胞移植(allo-HCT)的急性髓系白血病(AML)患者,比较接受ATG(251例,35%)与未接受ATG(473例,65%)患者的结局。结果显示ATG组II-IV级急性GVHD和慢性GVHD累积发生率显著降低,多因素分析中ATG与aGVHD、cGVHD及非复发死亡(NRM)风险降低独立相关,而复发风险、总生存和无白血病生存两组相似。

核心结论

  • 在AML患者基于TBI的清髓性预处理allo-HCT中加入ATG,可显著降低aGVHD和cGVHD,并转化为NRM显著降低,且不增加复发率。

研究设计与样本

  • 回顾性分析724例接受首次基于TBI的清髓性预处理allo-HCT的AML患者,其中ATG组251例(35%),非ATG组473例(65%)。
  • 存活患者中位随访59个月(四分位距28-83)。

主要发现

  • 两组复发风险、总生存和无白血病生存相似。

临床怎么用

  • 对于接受基于TBI的清髓性预处理allo-HCT的AML患者,加用ATG可降低GVHD和NRM而不增加复发风险。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of the use of antithymocyte globulin (ATG) following a total body irradiation (TBI)-based myeloablative conditioning regimen has been poorly explored. We retrospectively analyzed 724 patients who underwent a first allogeneic hematopoietic cell transplantation (allo-HCT) following a TBI-based conditioning regimen for acute myeloid leukemia (AML) and compared the outcomes of 251 (35%) patients who received ATG (ATG group) with 473 (65%) patients who did not (non-ATG group). Median follow-up of surviving patients was 59 months (interquartile range, 28-83). The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) for non-ATG and ATG groups in the first 100 days was 33% vs 24%, respectively (P = .0098). The 2-year cumulative incidence of chronic graft-versus-host disease (cGVHD) was reduced significantly in the ATG group in comparison with the non-ATG group (46% vs 34%, P = .003). Using multivariate analysis, in vivo T-cell depletion (ATG group) was independently associated with a decreased incidence of grade II-IV aGVHD (hazard ratio [HR], 0.28; P < .001), grade III-IV aGVHD (HR, 0.21; P < .001), cGVHD (HR, 0.63; P = .02), and nonrelapse mortality (NRM) (HR, 0.54; P = .02). Relapse risk, overall survival, and leukemia-free survival were similar between the 2 groups. Our results suggest that the addition of ATG to TBI-based myeloablative conditioning for allo-HCT in AML patients results in a significant reduction in aGVHD and cGVHD, translating into a significant reduction in NRM without increasing the relapse rate.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nagler A, Labopin M, Dholaria B, et al. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. Blood Adv. 2019. PMID: 31262738. doi:10.1182/bloodadvances.2019000030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。